Innovative use of topical calcineurin inhibitors

Dermatologic Clinics

Volumn 28, Issue 3, 2010, Pages 535-545

  Lin, Andrew N ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Calcineurin inhibitors; Pimecrolimus; Tacrolimus

Indexed keywords

BETAMETHASONE VALERATE; CALCIPOTRIOL; CALCITRIOL; CLOBETASOL PROPIONATE; CORTICOSTEROID; HYDROCORTISONE; KETOCONAZOLE; METHYLPREDNISOLONE; METRONIDAZOLE; PIMECROLIMUS; PLACEBO; TACROLIMUS; TRIAMCINOLONE ACETONIDE;

ABSENCE OF SIDE EFFECTS; ACNE VULGARIS; ACRODERMATITIS CHRONICA ATROPHICANS; ACTINIC KERATOSIS; ADJUVANT THERAPY; ALOPECIA; ALOPECIA AREATA; AMYLOIDOSIS; ANNULAR ERYTHEMA; BALANITIS; BEHCET DISEASE; BULLOUS SKIN DISEASE; CHEILITIS; CLINICAL TRIAL; CONTACT DERMATITIS; CROHN DISEASE; DERMATOMYOSITIS; DOSAGE SCHEDULE COMPARISON; DRUG ADMINISTRATION ROUTE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDICATION; DYSHIDROSIS; EPIDERMOLYSIS BULLOSA; ERYTHEMA; EXPERIMENTAL THERAPY; EXTERNAL OTITIS; FOLLICULITIS; FOX FORDYCE DISEASE; GENITAL PRURITUS; GIANT CELL GRANULOMA; GRAFT VERSUS HOST REACTION; GRANULOMA ANNULARE; HAILEY HAILEY DISEASE; HUMAN; ICHTHYOSIS; INCONTINENTIA PIGMENTI; INTERMETHOD COMPARISON; LEG ULCER; LICHEN AUREUS; LICHEN PLANUS; LICHEN SCLEROSUS ET ATROPHICUS; LICHEN STRIATUS; LICHENOID; LICHENOID ERUPTION; LOW LEVEL LASER THERAPY; LYMPHOCYTIC INFILTRATION; MORPHEA; MUCINOSIS; MYCOSIS FUNGOIDES; NECROBIOSIS LIPOIDICA; NETHERTON DISEASE; NEURODERMATITIS; NEVUS; OFF LABEL DRUG USE; OROFACIAL GRANULOMATOSIS; PANNICULITIS; PAPULAR RASH; PARANEOPLASTIC PEMPHIGUS; PARONYCHIA; PEMPHIGUS FOLIACEUS; PERIORAL DERMATITIS; PITYRIASIS; PITYRIASIS LICHENOIDES; PITYRIASIS RUBRA PILARIS; PLASMACYTOSIS; PRIORITY JOURNAL; PRURITUS; PSORIASIS; PUSTULE; PYODERMA GANGRENOSUM; REVIEW; RHEUMATOID ARTHRITIS; ROSACEA; SARCOIDOSIS; SCABIES; SCLERODERMA; SCLEROMYXEDEMA; SEBORRHEIC DERMATITIS; SKIN DISEASE; SKIN GRANULOMA; SKIN LUPUS ERYTHEMATOSUS; SKIN MANIFESTATION; TELANGIECTASIA; TOPICAL TREATMENT; ULTRAVIOLET B RADIATION; VITILIGO; VULVA PRURITUS; VULVITIS;

ADMINISTRATION, CUTANEOUS; CALCINEURIN; CHILD; CHILD, PRESCHOOL; CROHN DISEASE; DERMATITIS, ATOPIC; DERMATOLOGIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LICHEN PLANUS, ORAL; LUPUS ERYTHEMATOSUS, CUTANEOUS; MALE; OFF-LABEL USE; PSORIASIS; ROSACEA; SKIN DISEASES; TACROLIMUS; THERAPIES, INVESTIGATIONAL; VITILIGO;

EID: 77953257855     PISSN: 07338635     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.det.2010.03.008     Document Type: Review

References (166)

1. Corrocher G., Di Lorenzo G., Martinelli N., et al. Comparative effect of tacrolimus 0.1% ointment and clobetasol 0.05% ointment in patients with oral lichen planus. J Clin Periodontol 2008, 35(3):244-249.
2. Radfar L., Wild R.C., Suresh L. A comparative treatment study of topical tacrolimus and clobetasol in oral lichen planus. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008, 105(2):187-193.
3. Hodgson T.A., Sahni N., Kaliakatsou F., et al. Long-term efficacy and safety of topical tacrolimus in the management of ulcerative/erosive oral lichen planus. Eur J Dermatol 2003, 13(5):466-470.
4. Vente C., Reich K., Rupprecht R., et al. Erosive mucosal lichen planus: response to topical treatment with tacrolimus. Br J Dermatol 1999, 140(2):338-342.
5. Morrison L., Kratochvil F.J., Gorman A. An open trial of topical tacrolimus for erosive oral lichen planus. J Am Acad Dermatol 2002, 47(4):617-620.
6. Olivier V., Lacour J.P., Mousnier A., et al. Treatment of chronic erosive oral lichen planus with low concentrations of topical tacrolimus: an open prospective study. Arch Dermatol 2002, 138(10):1335-1338.
7. Kaliakatsou F., Hodgson T.A., Lewsey J.D., et al. Management of recalcitrant ulcerative oral lichen planus with topical tacrolimus. J Am Acad Dermatol 2002, 46(1):35-41.
8. Laeijendecker R., Tank B., Dekker S.K., et al. A comparison of treatment of oral lichen planus with topical tacrolimus and triamcinolone acetonide ointment. Acta Derm Venereol 2006, 86(3):227-229.
9. Thomson M.A., Hamburger J., Stewart D.G., et al. Treatment of erosive oral lichen planus with topical tacrolimus. J Dermatolog Treat 2004, 15(5):308-314.
10. Rozycki T.W., Rogers R.S., Pittelkow M.R., et al. Topical tacrolimus in the treatment of symptomatic oral lichen planus: a series of 13 patients. J Am Acad Dermatol 2002, 46(1):27-34.
11. Byrd J.A., Davis M.D., Bruce A.J., et al. Response of oral lichen planus to topical tacrolimus in 37 patients. Arch Dermatol 2004, 140(12):1508-1512.
12. Volz T., Caroli U., Ludtke H., et al. Pimecrolimus cream 1% in erosive oral lichen planus-a prospective randomized double-blind vehicle-controlled study. Br J Dermatol 2008, 159(4):936-941.
13. Passeron T., Lacour J.P., Fontas E., et al. Treatment of oral erosive lichen planus with 1% pimecrolimus cream: a double-blind, randomized, prospective trial with measurement of pimecrolimus levels in the blood. Arch Dermatol 2007, 143(4):472-476.
14. Gorouhi F., Solhpour A., Beitollahi J.M., et al. Randomized trial of pimecrolimus cream versus triamcinolone acetonide paste in the treatment of oral lichen planus. J Am Acad Dermatol 2007, 57(5):806-813.
15. Passeron T., Ostovari N., Zakaria W., et al. Topical tacrolimus and the 308-nm excimer laser: a synergistic combination for the treatment of vitiligo. Arch Dermatol 2004, 140(9):1065-1069.
16. Kawalek A.Z., Spencer J.M., Phelps R.G. Combined excimer laser and topical tacrolimus for the treatment of vitiligo: a pilot study. Dermatol Surg 2004, 30(2 Pt 1):130-135.
17. Mehrabi D., Pandya A.G. A randomized, placebo-controlled, double-blind trial comparing narrowband UV-B Plus 0.1% tacrolimus ointment with narrowband UV-B plus placebo in the treatment of generalized vitiligo. Arch Dermatol 2006, 142(7):927-929.
18. Lepe V., Moncada B., Castanedo-Cazares J.P., et al. A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo. Arch Dermatol 2003, 139(5):581-585.
19. Radakovic S., Breier-Maly J., Konschitzky R., et al. Response of vitiligo to once- vs. twice-daily topical tacrolimus: a controlled prospective, randomized, observer-blinded trial. J Eur Acad Dermatol Venereol 2009, 23(8):951-953.
20. Fai D., Cassano N., Vena G.A. Narrow-band UVB phototherapy combined with tacrolimus ointment in vitiligo: a review of 110 patients. J Eur Acad Dermatol Venereol 2007, 21(7):916-920.
21. Ostovari N., Passeron T., Lacour J.P., et al. Lack of efficacy of tacrolimus in the treatment of vitiligo in the absence of UV-B exposure. Arch Dermatol 2006, 142(2):252-253.
22. Xu A.Z., Wei D.M., Huang X.D., et al. Efficacy and safety of tacrolimus cream 0.1% in the treatment of vitiligo. Int J Dermatol 2009, 48(1):86-90.
23. Grimes P.E., Morris R., Avaniss-Aghajani E., et al. Topical tacrolimus therapy for vitiligo: therapeutic responses and skin messenger RNA expression of proinflammatory cytokines. J Am Acad Dermatol 2004, 51(1):52-61.
24. Hartmann A., Brocker E.B., Hamm H. Occlusive treatment enhances efficacy of tacrolimus 0.1% ointment in adult patients with vitiligo: results of a placebo-controlled 12-month prospective study. Acta Derm Venereol 2008, 88(5):474-479.
25. Tanghetti E.A. Tacrolimus ointment 0.1% produces repigmentation in patients with vitiligo: results of a prospective patient series. Cutis 2003, 71(2):158-162.
26. Kanwar A.J., Dogra S., Parsad D. Topical tacrolimus for treatment of childhood vitiligo in Asians. Clin Exp Dermatol 2004, 29(6):589-592.
27. Silverberg N.B., Lin P., Travis L., et al. Tacrolimus ointment promotes repigmentation of vitiligo in children: a review of 57 cases. J Am Acad Dermatol 2004, 51(5):760-766.
28. Choi C.W., Chang S.E., Bak H., et al. Topical immunomodulators are effective for treatment of vitiligo. J Dermatol 2008, 35(8):503-507.
29. Esfandiarpour I., Ekhlasi A., Farajzadeh S., et al. The efficacy of pimecrolimus 1% cream plus narrow-band ultraviolet B in the treatment of vitiligo: a double-blind, placebo-controlled clinical trial. J Dermatolog Treat 2009, 20(1):14-18.
30. Atwa M. Efficacy and safety of pimecrolimus (ASM 981) 1% in the treatment of vitiligo. J Am Acad Dermatol 2005, 52(3 Suppl 1):P168.
31. Dawid M., Veensalu M., Grassberger M., et al. Efficacy and safety of pimecrolimus cream 1% in adult patients with vitiligo: results of a randomized, double-blind, vehicle-controlled study. J Dtsch Dermatol Ges 2006, 4(11):942-946.
32. Seckin D., Eryilmaz A., Baba M. A double-blind randomized trial of 1% pimecrolimus versus 0.05% clobetasol propionate for the treatment of vitiligo. J Am Acad Dermatol 2007, 56(2 (Suppl 2)):AB170.
33. Boone B., Ongenae K., Van Geel N., et al. Topical pimecrolimus in the treatment of vitiligo. Eur J Dermatol 2007, 17(1):55-61.
34. Sendur N., Karaman G., Sanic N., et al. Topical pimecrolimus: a new horizon for vitiligo treatment?. J Dermatolog Treat 2006, 17(6):338-342.
35. Seirafi H., Farnaghi F., Firooz A., et al. Pimecrolimus cream in repigmentation of vitiligo. Dermatology 2007, 214(3):253-259.
36. Coskun B., Saral Y., Turgut D. Topical 0.05% clobetasol propionate versus 1% pimecrolimus ointment in vitiligo. Eur J Dermatol 2005, 15(2):88-91.
37. Mayoral F.A., Vega J.M., Stavisky H., et al. Retrospective analysis of pimecrolimus cream 1% for treatment of facial vitiligo. J Drugs Dermatol 2007, 6(5):517-521.
38. Bilac D.B., Ermertcan A.T., Sahin M.T., et al. Two therapeutic challenges: facial vitiligo successfully treated with 1% pimecrolimus cream and 0.005% calcipotriol cream. J Eur Acad Dermatol Venereol 2009, 23(1):72-73.
39. Mayoral F.A., Gonzalez C., Shah N.S., et al. Repigmentation of vitiligo with pimecrolimus cream: a case report. Dermatology 2003, 207(3):322-323.
40. Souza Leite R.M., Craveiro Leite A.A. Two therapeutic challenges: periocular and genital vitiligo in children successfully treated with pimecrolimus cream. Int J Dermatol 2007, 46:986-989.
41. Stinco G., Piccirillo F., Forcione M., et al. An open randomized study to compare narrow band UVB, topical pimecrolimus and topical tacrolimus in the treatment of vitiligo. Eur J Dermatol 2009, 19(6):588-593.
42. Farajzadeh S., Daraei Z., Esfandiarpour I., et al. The efficacy of pimecrolimus 1% cream combined with microdermabrasion in the treatment of nonsegmental childhood vitiligo: a randomized placebo-controlled study. Pediatr Dermatol 2009, 26(3):286-291.
43. Hui-Lan Y., Xiao-Yan H., Jian-Yong F., et al. Combination of 308-nm excimer laser with topical pimecrolimus for the treatment of childhood vitiligo. Pediatr Dermatol 2009, 26(3):354-356.
44. Lebwohl M., Freeman A.K., Chapman M.S., et al. Tacrolimus ointment is effective for facial and intertriginous psoriasis. J Am Acad Dermatol 2004, 51(5):723-730.
45. Carroll C.L., Clarke J., Camacho F., et al. Topical tacrolimus ointment combined with 6% salicylic acid gel for plaque psoriasis treatment. Arch Dermatol 2005, 141(1):43-46.
46. Remitz A., Reitamo S., Erkko P., et al. Tacrolimus ointment improves psoriasis in a microplaque assay. Br J Dermatol 1999, 141(1):103-107.
47. Liao Y.H., Chiu H.C., Tseng Y.S., et al. Comparison of cutaneous tolerance and efficacy of calcitriol 3 microg g(-1) ointment and tacrolimus 0.3 mg g(-1) ointment in chronic plaque psoriasis involving facial or genitofemoral areas: a double-blind, randomized controlled trial. Br J Dermatol 2007, 157(5):1005-1012.
48. Clayton T.H., Harrison P.V., Nicholls R., et al. Topical tacrolimus for facial psoriasis. Br J Dermatol 2003, 149(2):419-420.
49. Yamamoto T., Nishioka K. Topical tacrolimus: an effective therapy for facial psoriasis. Eur J Dermatol 2003, 13(5):471-473.
50. Rallis E., Nasiopoulou A., Kouskoukis C., et al. Successful treatment of genital and facial psoriasis with tacrolimus ointment 0.1%. Drugs Exp Clin Res 2005, 31(4):141-145.
51. Martin E.S., Herrera R.M., Umbert A.E., et al. Topical tacrolimus for the treatment of psoriasis on the face, genitalia, intertriginous areas and corporal plaques. J Drugs Dermatol 2006, 5(4):334-336.
52. Brune A., Miller D.W., Lin P., et al. Tacrolimus ointment is effective for psoriasis on the face and intertriginous areas in pediatric patients. Pediatr Dermatol 2007, 24(1):76-80.
53. Freeman A.K., Linowski G.J., Brady C., et al. Tacrolimus ointment for the treatment of psoriasis on the face and intertriginous areas. J Am Acad Dermatol 2003, 48(4):564-568.
54. Bissonnette R., Nigen S., Bolduc C. Efficacy and tolerability of topical tacrolimus ointment for the treatment of male genital psoriasis. J Cutan Med Surg 2008, 12(5):230-234.
55. Gribetz C., Ling M., Lebwohl M., et al. Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study. J Am Acad Dermatol 2004, 51(5):731-738.
56. Mrowietz U., Wustlich S., Hoexter G., et al. An experimental ointment formulation of pimecrolimus is effective in psoriasis without occlusion. Acta Derm Venereol 2003, 83(5):351-353.
57. Kreuter A., Sommer A., Hyun J., et al. 1% pimecrolimus, 0.005% calcipotriol, and 0.1% betamethasone in the treatment of intertriginous psoriasis: a double-blind, randomized controlled study. Arch Dermatol 2006, 142(9):1138-1143.
58. Jacobi A., Braeutigam M., Mahler V., et al. Pimecrolimus 1% cream in the treatment of facial psoriasis: a 16-week open-label study. Dermatology 2008, 216(2):133-136.
59. Belsito D., Wilson D.C., Warshaw E., et al. A prospective randomized clinical trial of 0.1% tacrolimus ointment in a model of chronic allergic contact dermatitis. J Am Acad Dermatol 2006, 55(1):40-46.
60. Saripalli Y.V., Gadzia J.E., Belsito D.V. Tacrolimus ointment 0.1% in the treatment of nickel-induced allergic contact dermatitis. J Am Acad Dermatol 2003, 49(3):477-482.
61. Pacor M.L., Di Lorenzo G., Martinelli N., et al. Tacrolimus ointment in nickel sulphate-induced steroid-resistant allergic contact dermatitis. Allergy Asthma Proc 2006, 27(6):527-531.
62. Queille-Roussel C., Graeber M., Thurston M., et al. SDZ ASM 981 is the first non-steroid that suppresses established nickel contact dermatitis elicited by allergen challenge. Contact Dermatitis 2000, 42(6):349-350.
63. Bhardwaj S.S., Jaimes J.P., Liu A., et al. A double-blind randomized placebo-controlled pilot study comparing topical immunomodulating agents and corticosteroids for treatment of experimentally induced nickel contact dermatitis. Dermatitis 2007, 18(1):26-31.
64. Katsarou A., Armenaka M., Vosynioti V., et al. Tacrolimus ointment 0.1% in the treatment of allergic contact eyelid dermatitis. J Eur Acad Dermatol Venereol 2009, 23(4):382-387.
65. Nakada T., Iijima M., Maibach H.I. Eyeglass frame allergic contact dermatitis: does tacrolimus prevent recurrences?. Contact Dermatitis 2005, 53(4):219-221.
66. Weissenbacher S., Traidl-Hoffmann C., Eyerich K., et al. Modulation of atopy patch test and skin prick test by pretreatment with 1% pimecrolimus cream. Int Arch Allergy Immunol 2006, 140(3):239-244.
67. Mensing C.O., Mensing C.H., Mensing H. Treatment with pimecrolimus cream 1% clears irritant dermatitis of the periocular region, face and neck. Int J Dermatol 2008, 47(9):960-964.
68. Erkek E., Kazkayasi M., Bozdogan O. Acute actinic cheilitis-like chemical irritant reaction following accidental contact with ethylene glycol-favorable response to topical 1% pimecrolimus cream: a case report. Cutan Ocul Toxicol 2008, 27(2):91-95.
69. Di Costanzo L., Balato N., Zagaria O., et al. Successful management of a delayed and persistent cutaneous reaction to jellyfish with pimecrolimus. J Dermatolog Treat 2009, 20(3):179-180.
70. Meshkinpour A., Sun J., Weinstein G. An open pilot study using tacrolimus ointment in the treatment of seborrheic dermatitis. J Am Acad Dermatol 2003, 49(1):145-147.
71. Braza T.J., DiCarlo J.B., Soon S.L., et al. Tacrolimus 0.1% ointment for seborrhoeic dermatitis: an open-label pilot study. Br J Dermatol 2003, 148(6):1242-1244.
72. Warshaw E.M., Wohlhuter R.J., Liu A., et al. Results of a randomized, double-blind, vehicle-controlled efficacy trial of pimecrolimus cream 1% for the treatment of moderate to severe facial seborrheic dermatitis. J Am Acad Dermatol 2007, 57(2):257-264.
73. Firooz A., Solhpour A., Gorouchi F., et al. Pimecrolimus cream, 1%, vs hydrocortisone acetate cream, 1%, in the treatment of facial seborrheic dermatitis: a randomized, investigator-blind, clinical trial. Arch Dermatol 2006, 142(8):1066-1067.
74. Koc E., Arca E., Kose O., et al. An open, randomized, prospective, comparative study of topical pimecrolimus 1% cream and topical ketoconazole 2% cream in the treatment of seborrheic dermatitis. J Dermatolog Treat 2009, 20(1):4-9.
75. Cicek D., Kandi B., Bakar S., et al. Pimecrolimus 1% cream, methylprednisolone aceponate 0.1% cream and metronidazole 0.75% gel in the treatment of seborrhoeic dermatitis: a randomized clinical study. J Dermatolog Treat 2009, 20(6):344-349.
76. Bamford J.T., Elliott B.A., Haller I.V. Tacrolimus effect on rosacea. J Am Acad Dermatol 2004, 50(1):107-108.
77. Garg G., Thami G.P. Clinical efficacy of tacrolimus in rosacea. J Eur Acad Dermatol Venereol 2009, 23(2):239-240.
78. Weissenbacher S., Merkl J., Hildebrandt B., et al. Pimecrolimus cream 1% for papulopustular rosacea: a randomized vehicle-controlled double-blind trial. Br J Dermatol 2007, 156(4):728-732.
79. Karabulut A.A., Izol Serel B., Eksioglu H.M. A randomized, single-blind, placebo-controlled, split-face study with pimecrolimus cream 1% for papulopustular rosacea. J Eur Acad Dermatol Venereol 2008, 22(6):729-734.
80. Koca R., Altinyazar H.C., Ankarali H., et al. A comparison of metronidazole 1% cream and pimecrolimus 1% cream in the treatment of patients with papulopustular rosacea: a randomized open-label clinical trial. Clin Exp Dermatol July 6, 2009, [Epub ahead of print].
81. Lee D.H., Li K., Suh D.H. Pimecrolimus 1% cream for the treatment of steroid-induced rosacea: an 8-week split-face clinical trial. Br J Dermatol 2008, 158(5):1069-1076.
82. Chu C.Y. An open-label pilot study to evaluate the safety and efficacy of topically applied pimecrolimus cream for the treatment of steroid-induced rosacea-like eruption. J Eur Acad Dermatol Venereol 2007, 21(4):484-490.
83. Tzung T.Y., Liu Y.S., Chang H.W. Tacrolimus vs. clobetasol propionate in the treatment of facial cutaneous lupus erythematosus: a randomized, double-blind, bilateral comparison study. Br J Dermatol 2007, 156(1):191-192.
84. Yoshimasu T., Ohtani T., Sakamoto T., et al. Topical FK506 (tacrolimus) therapy for facial erythematous lesions of cutaneous lupus erythematosus and dermatomyositis. Eur J Dermatol 2002, 12(1):50-52.
85. Walker S.L., Kirby B., Chalmers R.J. The effect of topical tacrolimus on severe recalcitrant chronic discoid lupus erythematosus. Br J Dermatol 2002, 147(2):405-406.
86. Bohm M., Gaubitz M., Luger T.A., et al. Topical tacrolimus as a therapeutic adjunct in patients with cutaneous lupus erythematosus. A report of three cases. Dermatology 2003, 207(4):381-385.
87. Kanekura T., Yoshii N., Terasaki K., et al. Efficacy of topical tacrolimus for treating the malar rash of systemic lupus erythematosus. Br J Dermatol 2003, 148(2):353-356.
88. Lampropoulos C.E., Sangle S., Harrison P., et al. Topical tacrolimus therapy of resistant cutaneous lesions in lupus erythematosus: a possible alternative. Rheumatology (Oxford) 2004, 43(11):1383-1385.
89. Druke A., Gambichler T., Altmeyer P., et al. 0.1% Tacrolimus ointment in a patient with subacute cutaneous lupus erythematosus. J Dermatolog Treat 2004, 15(1):63-64.
90. Sugano M., Shintani Y., Kobayashi K., et al. Successful treatment with topical tacrolimus in four cases of discoid lupus erythematosus. J Dermatol 2006, 33(12):887-891.
91. Heffernan M.P., Nelson M.M., Smith D.I., et al. 0.1% tacrolimus ointment in the treatment of discoid lupus erythematosus. Arch Dermatol 2005, 141(9):1170-1171.
92. Barikbin B., Givrad S., Yousefi M., et al. Pimecrolimus 1% cream versus betamethasone 17-valerate 0.1% cream in the treatment of facial discoid lupus erythematosus: a double-blind, randomized pilot study. Clin Exp Dermatol 2009, 34(7):776-780.
93. Tlacuilo-Parra A., Guevara-Gutierrez E., Gutierrez-Murillo F., et al. Pimecrolimus 1% cream for the treatment of discoid lupus erythematosus. Rheumatology (Oxford) 2005, 44(12):1564-1568.
94. Kreuter A., Gambichler T., Breuckmann F., et al. Pimecrolimus 1% cream for cutaneous lupus erythematosus. J Am Acad Dermatol 2004, 51(3):407-410.
95. Zabawski E. Treatment of cutaneous lupus with Elidel. Dermatol Online J 2002, 8(2):25.
96. Schwarz T., Kreiselmaier I., Bieber T., et al. A randomized, double-blind, vehicle-controlled study of 1% pimecrolimus cream in adult patients with perioral dermatitis. J Am Acad Dermatol 2008, 59(1):34-40.
97. Oppel T., Pavicic T., Kamann S., et al. Pimecrolimus cream (1%) efficacy in perioral dermatitis - results of a randomized, double-blind, vehicle-controlled study in 40 patients. J Eur Acad Dermatol Venereol 2007, 21(9):1175-1180.
98. Hart A.L., Plamondon S., Kamm M.A. Topical tacrolimus in the treatment of perianal Crohn's disease: exploratory randomized controlled trial. Inflamm Bowel Dis 2007, 13(3):245-253.
99. Casson D.H., Eltumi M., Tomlin S., et al. Topical tacrolimus may be effective in the treatment of oral and perineal Crohn's disease. Gut 2000, 47(3):436-440.
100. Russell R.K., Richardson N., Wilson D.C. Systemic absorption with complications during topical tacrolimus treatment for orofacial Crohn disease. J Pediatr Gastroenterol Nutr 2001, 32(2):207-208.
101. Hengge U.R., Krause W., Hofmann H., et al. Multicentre, phase II trial on the safety and efficacy of topical tacrolimus ointment for the treatment of lichen sclerosus. Br J Dermatol 2006, 155(5):1021-1028.
102. Virgili A., Lauriola M.M., Mantovani L., et al. Vulvar lichen sclerosus: 11 women treated with tacrolimus 0.1% ointment. Acta Derm Venereol 2007, 87(1):69-72.
103. Luesley D.M., Downey G.P. Topical tacrolimus in the management of lichen sclerosus. BJOG 2006, 113(7):832-834.
104. Ebert A.K., Rosch W.H., Vogt T. Safety and tolerability of adjuvant topical tacrolimus treatment in boys with lichen sclerosus: a prospective phase 2 study. Eur Urol 2008, 54(4):932-937.
105. Assmann T., Becker-Wegerich P., Grewe M., et al. Tacrolimus ointment for the treatment of vulvar lichen sclerosus. J Am Acad Dermatol 2003, 48(6):935-937.
106. Matsumoto Y., Yamamoto T., Isobe T., et al. Successful treatment of vulvar lichen sclerosus in a child with low-concentration topical tacrolimus ointment. J Dermatol 2007, 34(2):114-116.
107. Kunstfeld R., Kirnbauer R., Stingl G., et al. Successful treatment of vulvar lichen sclerosus with topical tacrolimus. Arch Dermatol 2003, 139(7):850-852.
108. Ginarte M., Toribio J. Vulvar lichen sclerosus successfully treated with topical tacrolimus. Eur J Obstet Gynecol Reprod Biol 2005, 123(1):123-124.
109. Bohm M., Frieling U., Luger T.A., et al. Successful treatment of anogenital lichen sclerosus with topical tacrolimus. Arch Dermatol 2003, 139(7):922-924.
110. Valdivielso-Ramos M., Bueno C., Hernanz J.M. Significant improvement in extensive lichen sclerosus with tacrolimus ointment and PUVA. Am J Clin Dermatol 2008, 9(3):175-179.
111. Wakamatsu J., Yamamoto T., Uchida H., et al. Lichen sclerosus et atrophicus of the lip: successful treatment with topical tacrolimus. J Eur Acad Dermatol Venereol 2008, 22(6):760-762.
112. Goldstein A.T., Marinoff S.C., Christopher K. Pimecrolimus for the treatment of vulvar lichen sclerosus: a report of 4 cases. J Reprod Med 2004, 49(10):778-780.
113. Nissi R., Eriksen H., Risteli J., et al. Pimecrolimus cream 1% in the treatment of lichen sclerosus. Gynecol Obstet Invest 2007, 63(3):151-154.
114. Oskay T., Sezer H.K., Genc C., et al. Pimecrolimus 1% cream in the treatment of vulvar lichen sclerosus in postmenopausal women. Int J Dermatol 2007, 46(5):527-532.
115. Goldstein A.T., Marinoff S.C., Christopher K. Pimecrolimus for the treatment of vulvar lichen sclerosus in a premenarchal girl. J Pediatr Adolesc Gynecol 2004, 17(1):35-37.
116. Arican O., Ciralik H., Sasmaz S. Unsuccessful treatment of extragenital lichen sclerosus with topical 1% pimecrolimus cream. J Dermatol 2004, 31(12):1014-1017.
117. Kroft E.B., Groeneveld T.J., Seyger M.M., et al. Efficacy of topical tacrolimus 0.1% in active plaque morphea: randomized, double-blind, emollient-controlled pilot study. Am J Clin Dermatol 2009, 10(3):181-187.
118. Stefanaki C., Stefanaki K., Kontochristopoulos G., et al. Topical tacrolimus 0.1% ointment in the treatment of localized scleroderma. An open label clinical and histological study. J Dermatol 2008, 35(11):712-718.
119. Allen A., Siegfried E., Silverman R., et al. Significant absorption of topical tacrolimus in 3 patients with Netherton syndrome. Arch Dermatol 2001, 137(6):747-750.
120. Price V.H., Willey A., Chen B.K. Topical tacrolimus in alopecia areata. J Am Acad Dermatol 2005, 52(1):138-139.
121. Feldmann K.A., Kunte C., Wollenberg A., et al. Is topical tacrolimus effective in alopecia areata universalis?. Br J Dermatol 2002, 147(5):1031-1032.
122. Park S.W., Kim J.W., Wang H.Y. Topical tacrolimus (FK506): treatment failure in four cases of alopecia universalis. Acta Derm Venereol 2002, 82(5):387-388.
123. Thiers B.H. Topical tacrolimus: treatment failure in a patient with alopecia areata. Arch Dermatol 2000, 136(1):124.
124. Duque M.I., Yosipovitch G., Fleischer A.B., et al. Lack of efficacy of tacrolimus ointment 0.1% for treatment of hemodialysis-related pruritus: a randomized, double-blind, vehicle-controlled study. J Am Acad Dermatol 2005, 52(3 Pt 1):519-521.
125. Clark-Loeser L., Latkowski J.A. Frontal fibrosing alopecia. Dermatol Online J 2005, 11(4):6.
126. Oh C.C., McKenna D.B., McLaren K.M., et al. Factitious panniculitis masquerading as pyoderma gangrenosum. Clin Exp Dermatol 2005, 30(3):253-255.
127. Gambichler T., Tomi N.S., Moussa G., et al. Topical tacrolimus neither prevents nor abolishes ultraviolet-induced erythema. J Am Acad Dermatol 2006, 55(5):882-885.
128. Rigopoulos D., Gregoriou S., Korfitis C., et al. Lack of response of alopecia areata to pimecrolimus cream. Clin Exp Dermatol 2007, 32(4):456-457.
129. Tan J.K., Morneau K., Fung K. Randomized controlled trial of pimecrolimus 1% cream for treatment of facial acne vulgaris. J Am Acad Dermatol 2005, 52(4):738-739.
130. Scope A., Lieb J.A., Dusza S.W., et al. A prospective randomized trial of topical pimecrolimus for cetuximab-associated acnelike eruption. J Am Acad Dermatol 2009, 61(4):614-620.
131. Eiling E., Brandt M., Schwarz T., et al. Pimecrolimus: a novel treatment for cetuximab-induced papulopustular eruption. Arch Dermatol 2008, 144(9):1236-1238.
132. Lin A. Topical calcineurin inhibitors. Comprehensive dermatologic drug therapy 2007, 671-691. Saunders-Elsevier, Philadelphia. 2nd edition. S. Wolverton (Ed.).
133. Patterson C., Coutts I. Granuloma faciale successfully treated with topical tacrolimus. Australas J Dermatol 2009, 50(3):217-219.
134. Rigopoulos D., Gregoriou S., Belyayeva E., et al. Efficacy and safety of tacrolimus ointment 0.1% vs. betamethasone 17-valerate 0.1% in the treatment of chronic paronychia: an unblinded randomized study. Br J Dermatol 2009, 160(4):858-860.
135. Al-Mutairi N., El-Khalawany M. Clinicopathological characteristics of lichen planus pigmentosus and its response to tacrolimus ointment: an open label, non-randomized, prospective study. J Eur Acad Dermatol Venereol October 15, 2009, DOI:10.1111/j.1468-3083.2009.03460.x.
136. Rigopoulos D., Gregoriou S., Charissi C., et al. Tacrolimus ointment 0.1% in pityriasis alba: an open-label, randomized, placebo-controlled study. Br J Dermatol 2006, 155(1):152-155.
137. Kleikamp S., Kutzner H., Frosch P.J. Annular lichenoid dermatitis of youth-a further case in a 12-year-old girl. J Dtsch Dermatol Ges 2008, 6(8):653-656.
138. Weisshaar E. Successful treatment of genital pruritus using topical immunomodulators as a single therapy in multi-morbid patients. Acta Derm Venereol 2008, 88(2):195-196.
139. Caffier P.P., Harth W., Mayelzadeh B., et al. Tacrolimus: a new option in therapy-resistant chronic external otitis. Laryngoscope 2007, 117(6):1046-1052.
140. Jessup C.J., Morgan S.C., Cohen L.M., et al. Incontinentia pigmenti: treatment of IP with topical tacrolimus. J Drugs Dermatol 2009, 8(10):944-946.
141. Jin S.P., Cho K.H., Huh C.H. Plasma cell cheilitis, successfully treated with topical 0.03% tacrolimus ointment. J Dermatolog Treat 2009, 1-3. DOI:10.1080/09546630903200620.
142. Kovich O.I., Cohen D.E. Granulomatous cheilitis. Dermatol Online J 2004, 10(3):10.
143. Mutasim D.F. Successful treatment of inflammatory linear verrucous epidermal nevus with tacrolimus and fluocinonide. J Cutan Med Surg 2006, 10(1):45-47.
144. Tomi N.S., Altmeyer P., Kreuter A. Tacrolimus ointment for 'jogger's nipples'. Clin Exp Dermatol 2007, 32(1):106-107.
145. Shipley D.R., Kennedy C.T. Juvenile plantar dermatosis responding to topical tacrolimus ointment. Clin Exp Dermatol 2006, 31(3):453-454.
146. Miller S. The effect of tacrolimus on lower extremity ulcers: a case study and review of the literature. Ostomy Wound Manage 2008, 54(4):36-42.
147. Rongioletti F., Zaccaria E., Cozzani E., et al. Treatment of localized lichen myxedematosus of discrete type with tacrolimus ointment. J Am Acad Dermatol 2008, 58(3):530-532.
148. Aschoff R., Wozel G. Topical tacrolimus for the treatment of lichen simplex chronicus. J Dermatolog Treat 2007, 18(2):115-117.
149. Campbell F.A., Gupta G. Lichenoid tattoo reaction responding to topical tacrolimus ointment. Clin Exp Dermatol 2006, 31(2):293-294.
150. Dauendorffer J.N., Mahe E., Saiag P. Tacrolimus ointment, an interesting adjunctive therapy for childhood linear IgA bullous dermatosis. J Eur Acad Dermatol Venereol 2008, 22(3):364-365.
151. Rallis E., Economidi A., Verros C., et al. Successful treatment of patch type mycosis fungoides with tacrolimus ointment 0.1%. J Drugs Dermatol 2006, 5(9):906-907.
152. Manzur A., Siddiqui A.H. Necrolytic acral erythema: successful treatment with topical tacrolimus ointment. Int J Dermatol 2008, 47(10):1073-1075.
153. Virgili A., Mantovani L., Lauriola M.M., et al. Tacrolimus 0.1% ointment: is it really effective in plasma cell vulvitis? Report of four cases. Dermatology 2008, 216(3):243-246.
154. Dissemond J., Knab J., Lehnen M., et al. Successful treatment of stasis dermatitis with topical tacrolimus. Vasa 2004, 33(4):260-262.
155. Erkek E., Sahin S., Kilic R., et al. A case of cheilitis glandularis superimposed on oral lichen planus: successful palliative treatment with topical tacrolimus and pimecrolimus. J Eur Acad Dermatol Venereol 2007, 21(7):999-1000.
156. Day I., Lin A.N. Use of pimecrolimus cream in disorders other than atopic dermatitis. J Cutan Med Surg 2008, 12(1):17-26.
157. Kelekci H.K., Uncu H.G., Yilmaz B., et al. Pimecrolimus 1% cream for pruritus in postmenopausal diabetic women with vulvar lichen simplex chronicus: a prospective non-controlled case series. J Dermatolog Treat 2008, 19(5):274-278.
158. Katoulis A., Georgala S., Bozi E., et al. Frontal fibrosing alopecia: treatment with oral dutasteride and topical pimecrolimus. J Eur Acad Dermatol Venereol 2009, 23(5):580-582.
159. Schurmeyer-Horst F., Luger T.A., Bohm M. Long-term efficacy of occlusive therapy with topical pimecrolimus in severe dyshidrosiform hand and foot eczema. Dermatology 2007, 214(1):99-100.
160. Tan C., Zhu W.Y., Min Z.S. A case of recurrent eruptive pseudo-angiomatosis that responded well to pimecrolimus 1% cream. Dermatology 2009, 218(2):181-183.
161. Gorpelioglu C., Sarifakioglu E., Bayrak R. A case of follicular mucinosis treated successfully with pimecrolimus. Clin Exp Dermatol 2009, 34(1):86-87.
162. Gregoriou S., Argyriou G., Christofidou E., et al. Treatment of pityriasis rubra pilaris with pimecrolimus cream 1%. J Drugs Dermatol 2007, 6(3):340-342.
163. Bellini V., Simonetti S., Lisi P. Successful treatment of severe pyoderma gangrenosum with pimecrolimus cream 1%. J Eur Acad Dermatol Venereol 2008, 22(1):113-115.
164. Mansouri P., Farshi S., Nahavandi A., et al. Pimecrolimus 1 percent cream and pulsed dye laser in treatment of a patient with reticular erythematous mucinosis syndrome. Dermatol Online J 2007, 13(2):22.
165. Bardazzi F., Antonucci A., Savoia F., et al. Two cases of Zoon's balanitis treated with pimecrolimus 1% cream. Int J Dermatol 2008, 47(2):198-201.
166. Fujita W.H., McCormick C.L., Parneix-Spake A. An exploratory study to evaluate the efficacy of pimecrolimus cream 1% for the treatment of pityriasis alba. Int J Dermatol 2007, 46(7):700-705.